Drug intelligence / Profile preview

ornithine phenylacetate

Development stage
Phase 3
Lead developer
Mallinckrodt
Modality
Small Molecules
Administration
Intravenous, Oral
01

Overview

**Ornithine phenylacetate** is an investigational small-molecule ammonia-scavenging agent developed for hyperammonemia associated with advanced liver disease, particularly overt hepatic encephalopathy. It is a single crystalline salt composed of L-ornithine and phenylacetate. L-ornithine promotes peripheral ammonia incorporation into glutamine through glutamine synthetase, while phenylacetate conjugates glutamine to form phenylacetylglutamine, which is eliminated in urine; together these actions provide a non-urea-cycle route for net nitrogen removal. The program has been developed as intravenous and oral formulations, including OCR-002, MNK6105, MNK6106, YAQ006, and YAQ007. Yaqrit and its subsidiary Amalive are advancing intravenous and oral formulations for acute treatment and recurrence prevention of hepatic encephalopathy.

Other names
L-ornithine phenylacetateL-OPAOPAL-ornithine salt of phenylacetic acid
02

Targets

GLUL (Glutamine synthetase)GLS1 (Glutaminase 1)

Beyond the preview

Go deeper on ornithine phenylacetate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ornithine phenylacetate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call